DrCarney.com Blog
Association Between Androgen Deprivation Therapy and Risk of Dementia.
Androgen deprivation therapy may promote the development of dementia in patients with prostate cancer.
This research work investigated the hypothesis that androgen deprivation therapy (ADT) can increase the risk of dementia in prostate cancer patients. Scientists from Stanford University School of Medicine looked at use of androgen deprivation drugs in comparison with the incidence rates of dementia among 9,272 patients with prostate cancer.
The team of investigators found out that exposure to androgen deprivation therapy raised the risk of dementia in prostate cancer patients. The data from this study indicate that prostate cancer patients treated with androgen deprivation therapy may be highly prone to suffer from dementia.
Research Summary Information
-
2017
-
Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH.
-
Stanford Center for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, California2Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia. Stanford Center for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, California. Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California. Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California.
-
Yes, Free full text of study was found:
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.
About the author
